Genuine Biotech Limited

真实生物科技有限公司

Develops, manufactures and commercializes novel drugs for viral infections, oncology and cardio-cerebrovascular diseases in China, with a portfolio of seven candidates centered on azvudine for HIV and COVID-19, plus CL-197 and dosimertinib.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Distribution model
• Reliance on platforms, partners or licences
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Capacity and utilisation
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Preferred shares and fair-value liabilities
• Non-recurring gains and losses
• Chapter 18A biotech
• Other